Drug Information

Drug General Information
Drug ID
D01CXW
Former ID
DIB000261
Drug Name
MEDI0680
Drug Type
Antibody
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 1 [544457]
Company
Medimmune
Target and Pathway
Target(s) PD-1 Target Info [544457]
KEGG Pathway Cell adhesion molecules (CAMs)
T cell receptor signaling pathway
Reactome PD-1 signaling
WikiPathways T-Cell Receptor and Co-stimulatory Signaling
Costimulation by the CD28 family
References
Ref 544457A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas. J Immunother Cancer. 2014; 2(Suppl 3): P73.
Ref 544457A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas. J Immunother Cancer. 2014; 2(Suppl 3): P73.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.